カテゴリ： GlobalData, イスラエル, 企業調査

Teva Pharmaceutical Industries Ltd (TEVA)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Teva Pharmaceutical Industries Ltd (TEVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9930
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：310
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：イスラエル
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Teva Pharmaceutical Industries Ltd (Teva) is a pharmaceutical company that carries out the research, development, manufacture and commercialization of generic and specialty medicines. It provides specialty medicines to treat disorders of the central nervous system (CNS), respiratory, cancer, women’s health and other therapy areas. The company offers generic medicines in a range of dosage forms including capsules, tablets, injectables, liquids, inhalants, creams and ointments. Teva also provides over-the-counter (OTC) products, besides active pharmaceutical ingredients (APIs). It carries out OTC business principally through PGT Healthcare, a consumer healthcare joint venture with The Procter & Gamble Company (P&G). The company conducts its worldwide operations through a network of global subsidiaries. Teva is headquartered in Petach Tikva, Israel.

Teva Pharmaceutical Industries Ltd (TEVA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 8
List of Figures 10
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 12
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 13
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 14
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 15
Teva Pharmaceutical Industries Ltd, Medical Devices Deals, 2012 to YTD 2018 17
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 18
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deal Details 27
Asset Purchase 27
Taiyo Pharma to Acquire Product Rights from Chugai Pharma and Roche 27
Teva Pharma Acquires Generics Drug Business from Allergan for USD39 Billion 29
Labrys Biologics Acquires RN-307 from Pfizer 31
Teva Completes Acquisition Of Huntexil Development Program Rights From NeuroSearch For US$26 Million 32
Venture Financing 34
Auspex Pharma Raises US$20 Million In Series E Financing 34
Labrys Biologics Raises US$31 Million In Series A Financing 36
Auspex Pharma Raises US$25 Million In Series D Financing 38
Auspex Pharma Raises US$1.5 Million In Venture Financing 39
Gamida Cell Raises US$10 Million In Series E Financing 40
Teva Pharma Industries Invests In MultiGene Vascular Systems 42
Private Equity 43
CVC Capital Partners Acquires Women Health Portfolio from Teva Pharma for USD703 Million 43
Partnerships 45
Teva Pharma May Form Joint Venture with Guangzhou Pharma 45
Teva Pharma and Nuvelution Pharma Enter into Agreement 46
AbCellera Biologics Enters into Research Agreement with Teva Pharma 47
Teva Pharma Enters into Distribution Agreement with Celltrion 48
Regeneron Pharma Enters into Co-Development Agreement with Teva Pharma for Fasinumab 49
Teva Pharma and Takeda Pharma Form Joint Venture 50
Teva Pharma Enters into Research Agreement with AbCellera Biologics 52
Egalet Enters into Agreement with Teva Pharma 53
Teva Pharma Partners with University College London and Imanova 54
Teva Pharma Enters into an Agreement with Microchips Biotech 55
Medpro Pharma to Enter into Distribution Agreement with Teva Pharma 56
Venus Remedies Enters into Agreement with Teva Pharma for Anti Cancer Drug 57
Abic Marketing Enters into Agreement with Arena Pharma 58
Teva Pharma Industries to Form Joint Venture with Philips Medical Systems 59
Teva Pharma Enters Into Agreement With Takeda Pharma To Commercialize Rasagiline In Japan 60
Cancer Research Technology And Teva Enter Into R&D Agreement To Develop Cancer Drugs 61
Champions Enters Into Drug Discovery And Development Agreement With Teva 62
Teva Pharma Plans To Enter Into Partnerships 63
Teva Pharma Enters Into Agreement With Perrigo For Generic Temozolomide 64
Teva Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 65
Teva Pharma To Form Joint Venture With Handok Pharma 67
Teva Pharma Enters Into Co-Marketing Agreement With CTC Bio For Sildenafil 68
Galena Biopharma Enters Into Commercialization Agreement With Teva Pharma For NeuVax 69
Teva Pharma And Proctor & Gamble Finalize Joint Venture 70
Licensing Agreements 72
Theramex Enters into Licensing Agreement with Endoceutics 72
Teva Pharma Enters into Licensing Agreement with Alder Biopharma 73
Otsuka Pharma Enters into Licensing Agreement with Teva Pharma for TEV-48125 74
Teva Pharma Enters into Licensing Agreement with Takeda for Attenukine 75
Teva Pharma Enters into Licensing Agreement with CSPC Zhongqi Pharma 76
Teva Pharma Enters into Licensing Agreement with Takeda Pharma for Ninlaro 77
Watson Labs Enters into Licensing Agreement with CSPC Pharma 78
Checkpoint Therapeutics Enters into Licensing Agreement with Cephalon 79
Teva Pharma Amends Licensing Agreement with Eagle Pharma for EP-3102 80
Intellipharmaceutics Enters into Licensing Agreement with Teva Pharma 81
Auspex Pharma Enters into Licensing Agreement with Imphar 82
QRxPharma Enters Into Licensing Agreement With Teva Pharma For Moxduo 83
Pierre Fabre Enters into Licensing Agreement with Medis 84
Teva Pharma Enters Into Licensing Agreement With Takeda Pharma For Glatiramer Acetate 85
BioAlliance Pharma Enters Into Licensing Agreement With Teva Pharma For Sitavig 87
Equity Offering 88
Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 88
Teva Pharma Announces Underwriters Exercise of Over-Allotment of American Depositary Shares 90
Teva Pharma Announces Underwriters Exercise of Over-Allotment of Preferred Shares 92
American Well Raises USD10 Million in Private Placement of Shares 94
Ignyta Raises USD42 Million in Private Placement of Shares 95
Auspex Pharma Raises USD203.4 Million in Public Offering of Shares 96
Auspex Pharma Raises USD69.7 Million in Public Offering of Shares 98
Auspex Pharma Completes IPO For US$96.6 Million 100
Debt Offering 102
Teva Pharma Prices Private Placement of 6% Notes Due 2024 for USD1.25 Billion 102
Teva Pharma Prices Private Placement of 6.75% Notes Due 2028 for USD1.25 Billion 103
Teva Pharma Prices Private Placement of 3.25% Notes Due 2022 for USD866.3 Million 104
Teva Pharma Prices Private Placement of 4.5% Notes Due 2025 for USD1,113.8 Million 105
Teva Pharma Plans to Raise USD5,000 Million in Public Offering of Debt Securities 106
Teva Pharma Raises USD304 Million in Public Offering of 0.125% Notes Due 2018 107
Teva Pharma Raises USD354.6 Million in Public Offering of 1% Notes Due 2025 109
Teva Pharma Raises USD354.6 Million in Public Offering of 0.5% Notes Due 2022 111
Teva Pharma Raises USD1.65 Billion in Additional Public Offering of 1.125% Notes Due 2024 113
Teva Pharma Raises USD1.93 Billion in Additional Public Offering of 0.375% Notes Due 2020 115
Teva Pharma Raises USD820 Million in Additional Public Offering of 1.625% Notes Due 2028 117
Teva Pharma Raises USD3 Billion in Public Offering of 2.8% Notes Due 2023 119
Teva Pharma Raises USD1.5 Billion in Public Offering of 1.4% Notes Due 2018 121
Teva Pharma Raises USD2 Billion in Public Offering of 1.7% Notes Due 2019 123
Teva Pharma Raises USD2 Billion in Public Offering of 4.1% Notes Due 2046 125
Teva Pharma Raises USD3.5 Billion in Public Offering of 3.15% Notes Due 2026 127
Teva Pharma Raises USD3 Billion in Public Offering of 2.2% Notes Due 2021 129
Teva Pharma Plans to Raise USD22 Billion in Public Offering of Bonds 131
Teva Pharma Raises USD1.4 Billion in Public Offering of 1.25% Senior Notes Due 2023 132
Teva Pharma Raises USD760 Million in Public Offering of 1.875% Senior Notes Due 2027 133
Teva Pharma Completes Public Offering Of Notes Due 2020 For US$700 Million 134
Teva Pharma Completes Public Offering Of Notes Due 2022 For US$1.3 Billion 136
Teva Pharma Completes Public Offering Of Senior Notes Due 2018 For US$495 Million 138
Teva Pharma Completes Public Offering Of Senior Notes Due 2019 For US$1.3 Billion 140
Asset Transactions 142
89bio Acquires NASH Assets from Teva Pharma 142
NeuroSearch Sells Rights for Pridopidine to Teva Pharma 143
Super-Pharm May Acquire Ashdod Plant from Teva Pharma Industries 144
Foundation Consumer Healthcare Acquires Women Health Products from Teva Pharma for USD675 Million 145
Teva Pharma May Sell European Oncology and Pain Assets 146
Intas Pharma and Aurobindo Pharma May Acquire Europen Divisions from Teva Pharma 147
Teva Pharma May sell Medis Unit 148
OncBioMune Pharma Acquire Norepinefrine in Mexico from Teva Pharma 149
Teva Pharma Sells Assets and Operations of Actavis Generics in UK and Ireland to Accord Healthcare 150
Arrow Generiques to Acquire Select Commercial Products in France from Teva Pharma 152
Sagent Pharma Acquires Product Portfolio from Teva Pharma and Actavis for USD40 Million 153
Mayne Pharma Acquires US Generic Products from Teva Pharma and Allergan for USD652 Million 154
Impax Labs Acquires Generic Products from Teva Pharma and Allergan for USD586 Million 156
Dr. Reddy’s Labs Acquires Portfolio of Eight ANDAs from Teva Pharma for USD350 Million 158
Cipla and Aurobindo Acquires Certain Generic Products Rights in the US from Teva Pharma 160
Perrigo Acquires Remaining 60.9% Rights of Benzaclin from Barr Labs for USD62 Million 161
Prasco to Acquire Authorized Generic of Adderall XR Capsules from Teva Pharma and Shire 162
Zydus Cadila Healthcare Announces Acquisition of Two Abbreviated New Drug Applications form Teva Pharma 163
Saniona Acquires ACR325 and ACR343 Drugs from NeuroSearch 164
Teva Pharma May Divest its Assets 165
Ferring Pharma Acquires Global Rights to Milprosa from Teva Women’s Health 167
ANI Pharma Acquires Rights to Testosterone Gel 1% from Teva Pharma 168
Amneal Pharma Acquires Generic Business of Actavis Australia 169
Teva Pharma Plans to Divest Some Operations 170
Ignyta Acquires Four Oncology R&D Assets from Cephalon 171
ANI Pharma Acquires ANDA from Teva Pharma 173
Teva Pharma to Sell its Manufacturing Facility in Sellersville, Pennsylvania to G&W Labs 174
Saniona Acquires Assets from NeuroSearch 175
ANI Pharma Acquires 22 Generic Drug Products from Teva Pharma 176
Amedra Pharmaceuticals Acquires Mebendazole Tablet Product from Teva Pharmaceutical 177
Teva Pharma Plans To Sell Manufacturing Facility In Irvine, California 178
CleveXel Pharma Acquires Development Center From Teva Pharma 179
Saniona Acquires Technical Platforms from NeuroSearch 180
Procter & Gamble Receives EC Approval To Acquire OTC Business Of Teva Pharma 181
Teva Completes Acquisition Of Huntexil Development Program Rights From NeuroSearch For US$26 Million 182
Aniona Acquires Portfolio of Preclinical Assets from NeuroSearch 184
Halo Pharma Completes Acquisition Of Mirabel Manufacturing Facility From Teva Canada 185
Hi-Tech Pharmacal Acquires Rights To Cormax From Watson Labs 186
Acquisition 187
Biolab Sanus Farmaceutica Acquires Actavis Farmaceutica from Teva Pharma and Actavis Dutch 187
NeuroSearch Plans to Sell Itself 188
Allergan to Sell 10% Stake in Teva Pharma 189
Teva Pharma Sells Stake in Mesoblast 190
Jiaxing Yun Shi Tai Yu Investment to Acquire 20% Stake in Tianjin Sinobioway Biomedicine from Tianjin Zhongxin Pharma 191
Clal Biotech to Acquire 5% Stake in Gamida Cell from Teva Pharma 192
Teva Pharma Acquires Anda from Allergan for USD500 Million 193
Teva Pharma, Mylan May Acquire Teut|Pfizer 194
Teva Pharma Acquires Rimsa for USD2.3 Billion 196
Auspex Pharma Acquires Imphar 197
Teva Pharma Acquires Gecko Health Innovations 198
Teva Pharma to Acquire 51% Stake in Immuneering 199
Teva Pharma Acquires Auspex Pharma 200
Teva Pharma Completes Acquisition of Labrys Biologics 202
Teva Pharma Completes Acquisition Of NuPathe 203
Zhejiang Chiral Medicine Chemicals To Acquire Stake In Actavis (Foshan) Pharma From Actavis 205
Teva Pharma Completes Acquisition of MicroDose Therapeutx 206
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 207
BioTime Acquires 62.6% Stake in Cell Cure Neurosciences for USD3.5 Million 209
XTL Biopharma Acquires 31% Stake In Proteologics From Teva For US$2 Million 211
Teva Pharma Rumored To Acquire Amarin 212
Watson Pharma Acquires Ascent Pharmahealth From Strides Arcolab And Dennis Bastas For US$394 Million 213
Teva Pharmaceutical Industries Ltd – Key Competitors 215
Teva Pharmaceutical Industries Ltd – Key Employees 216
Teva Pharmaceutical Industries Ltd – Locations And Subsidiaries 218
Head Office 218
Other Locations & Subsidiaries 218
Joint Venture 226
Recent Developments 228
Strategy And Business Planning 228
Sep 07, 2018: Teva returns laquinimod global rights to Active Biotech 228
Financial Announcements 229
Nov 01, 2018: Teva reports third quarter 2018 financial results 229
Aug 02, 2018: Teva reports second quarter 2018 financial results 234
May 03, 2018: Teva Reports First Quarter 2018 Financial Results 239
Feb 08, 2018: Teva Reports 2017 Full Year and Fourth Quarter Financial Results 244
Nov 02, 2017: Teva Reports Third Quarter 2017 Financial Results 252
Aug 03, 2017: Teva Reports Second Quarter 2017 Financial Results 256
May 11, 2017: Teva Reports First Quarter 2017 Financial Results 258
Feb 13, 2017: Teva Reports Full Year and Fourth Quarter 2016 Financial Results 262
Jan 06, 2017: Teva Provides 2017 Financial Outlook 270
Corporate Communications 272
Dec 15, 2017: Drugmaker Teva to cut 14,000 jobs globally 272
Dec 12, 2017: Teva Pharmaceutical Industries: Dr. Yitzhak Peterburg, a member of the Board of Directors Resignation 273
Oct 30, 2017: Kare Schultz to Join Teva as President and Chief Executive Officer 274
Sep 11, 2017: Teva Names Kare Schultz as President and Chief Executive Officer 275
Jul 23, 2017: Teva to Terminate Around 300 jobs in Israel 277
Jul 13, 2017: Teva Enhances Board of Directors as All Proposals Approved at Annual General Meeting of Shareholders 278
Apr 26, 2017: Teva Announces Planned Departure of Eyal Desheh, Group Executive Vice President and Chief Financial Officer 279
Feb 06, 2017: Teva Appoints Dr. Yitzhak Peterburg as Interim Chief Executive Officer, Succeeding Erez Vigodman 280
Legal and Regulatory 282
Sep 07, 2018: SEC Charges Microcap Fraudsters for Roles in Lucrative Market Manipulation Schemes 282
May 31, 2017: Attorney General DeWine Files Lawsuit Against Opioid Manufacturers for Fraudulent Marketing; Fueling Opioid Epidemic 283
Government and Public Interest 284
Aug 16, 2018: The ALS Association and Teva grant two awards as part of the Teva CNS target identification crowdsourcing challenge 284
Product News 285
10/19/2017: Teva to Highlight New Data on COPAXONE at Joint ECTRIMS – ACTRIMS Congress in Paris 285
10/10/2018: Teva presents 25-year safety data from longest continuous trial of COPAXONE (glatiramer acetate injection) for the treatment of relapsing forms of Multiple Sclerosis 287
10/08/2018: Teva to Present New Data at 34th European Committee for Treatment and Research in Multiple Sclerosis Congress in Berlin 288
10/04/2017: Teva Comments on Anticipated At-Risk U.S. Launch of Generic Glatiramer Acetate 40mg/mL and Launch of Generic Glatiramer Acetate 20mg/mL 289
Jul 19, 2018: A Public Service Announcement from Beebe Healthcare- By Jeffrey E. Hawtof, MD, FAAFP, VP of Medical Operations and Informatics 290
Jul 16, 2018: FDA recalls valsartan drug products after impurity detection 291
Jul 16, 2018: Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of Valsartan and Valsartan Hydrochlorothiazide Tablets 292
05/05/2017: Teva Announces Publication of COPAXONE (glatiramer acetate injection) Pregnancy Data in the International Journal of MS Care 293
04/27/2018: Teva Presents New Long-Term Data Demonstrating Efficacy and Safety of COPAXONE (glatiramer acetate injection) 40 mg/mL 294
04/19/2017: Teva to Present Data on COPAXONE at 69th Annual Meeting of the American Academy of Neurology 295
04/17/2018: Teva to Present New Data on COPAXONE at 70th Annual Meeting of the American Academy of Neurology 296
04/03/2017: Teva Receives Positive Outcome for COPAXONE 40 mg/ml 3 Times Weekly Label in Europe 297
01/31/2017: Momenta Pharmaceuticals Announces District Court Decision to Invalidate Teva Pharmaceuticals Patents in COPAXONE (glatiramer acetate injection) 40 mg/mL Litigation 298
01/30/2017: Teva Confirms District Court Decision in COPAXONE 40 mg/mL Patent Trial 299
Other Significant Developments 300
Oct 21, 2018: Teva and New Jersey Governor Murphy formalize North America headquarters move with ceremony in Israel 300
Oct 11, 2018: Teva draws on patient experience to empower those living with chronic conditions 301
Sep 06, 2018: Teva Pharmaceuticals Europe: Patients research online – but are uncertain whether they can trust the results 302
Jul 17, 2018: Teva Highlights Key Milestones Achieved in the 2017 Social Impact Report 308
Oct 19, 2017: Teva: New Belief-based Patient Support Programme (PSP) Launched for People With Relapsing Multiple Sclerosis 309
Appendix 310
Methodology 310
About GlobalData 310
Contact Us 310
Disclaimer 310

List of Tables
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 12
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 13
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 14
Teva Pharmaceutical Industries Ltd, Deals By Therapy Area, 2012 to YTD 2018 15
Teva Pharmaceutical Industries Ltd, Medical Devices Deals, 2012 to YTD 2018 17
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 18
Taiyo Pharma to Acquire Product Rights from Chugai Pharma and Roche 27
Teva Pharma Acquires Generics Drug Business from Allergan for USD39 Billion 29
Labrys Biologics Acquires RN-307 from Pfizer 31
Teva Completes Acquisition Of Huntexil Development Program Rights From NeuroSearch For US$26 Million 32
Auspex Pharma Raises US$20 Million In Series E Financing 34
Labrys Biologics Raises US$31 Million In Series A Financing 36
Auspex Pharma Raises US$25 Million In Series D Financing 38
Auspex Pharma Raises US$1.5 Million In Venture Financing 39
Gamida Cell Raises US$10 Million In Series E Financing 40
Teva Pharma Industries Invests In MultiGene Vascular Systems 42
CVC Capital Partners Acquires Women Health Portfolio from Teva Pharma for USD703 Million 43
Teva Pharma May Form Joint Venture with Guangzhou Pharma 45
Teva Pharma and Nuvelution Pharma Enter into Agreement 46
AbCellera Biologics Enters into Research Agreement with Teva Pharma 47
Teva Pharma Enters into Distribution Agreement with Celltrion 48
Regeneron Pharma Enters into Co-Development Agreement with Teva Pharma for Fasinumab 49
Teva Pharma and Takeda Pharma Form Joint Venture 50
Teva Pharma Enters into Research Agreement with AbCellera Biologics 52
Egalet Enters into Agreement with Teva Pharma 53
Teva Pharma Partners with University College London and Imanova 54
Teva Pharma Enters into an Agreement with Microchips Biotech 55
Medpro Pharma to Enter into Distribution Agreement with Teva Pharma 56
Venus Remedies Enters into Agreement with Teva Pharma for Anti Cancer Drug 57
Abic Marketing Enters into Agreement with Arena Pharma 58
Teva Pharma Industries to Form Joint Venture with Philips Medical Systems 59
Teva Pharma Enters Into Agreement With Takeda Pharma To Commercialize Rasagiline In Japan 60
Cancer Research Technology And Teva Enter Into R&D Agreement To Develop Cancer Drugs 61
Champions Enters Into Drug Discovery And Development Agreement With Teva 62
Teva Pharma Plans To Enter Into Partnerships 63
Teva Pharma Enters Into Agreement With Perrigo For Generic Temozolomide 64
Teva Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 65
Teva Pharma To Form Joint Venture With Handok Pharma 67
Teva Pharma Enters Into Co-Marketing Agreement With CTC Bio For Sildenafil 68
Galena Biopharma Enters Into Commercialization Agreement With Teva Pharma For NeuVax 69
Teva Pharma And Proctor & Gamble Finalize Joint Venture 70
Theramex Enters into Licensing Agreement with Endoceutics 72
Teva Pharma Enters into Licensing Agreement with Alder Biopharma 73
Otsuka Pharma Enters into Licensing Agreement with Teva Pharma for TEV-48125 74
Teva Pharma Enters into Licensing Agreement with Takeda for Attenukine 75
Teva Pharma Enters into Licensing Agreement with CSPC Zhongqi Pharma 76
Teva Pharma Enters into Licensing Agreement with Takeda Pharma for Ninlaro 77
Watson Labs Enters into Licensing Agreement with CSPC Pharma 78
Checkpoint Therapeutics Enters into Licensing Agreement with Cephalon 79
Teva Pharma Amends Licensing Agreement with Eagle Pharma for EP-3102 80
Intellipharmaceutics Enters into Licensing Agreement with Teva Pharma 81
Auspex Pharma Enters into Licensing Agreement with Imphar 82
QRxPharma Enters Into Licensing Agreement With Teva Pharma For Moxduo 83
Pierre Fabre Enters into Licensing Agreement with Medis 84
Teva Pharma Enters Into Licensing Agreement With Takeda Pharma For Glatiramer Acetate 85
BioAlliance Pharma Enters Into Licensing Agreement With Teva Pharma For Sitavig 87
Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 88
Teva Pharma Announces Underwriters Exercise of Over-Allotment of American Depositary Shares 90
Teva Pharma Announces Underwriters Exercise of Over-Allotment of Preferred Shares 92
American Well Raises USD10 Million in Private Placement of Shares 94
Ignyta Raises USD42 Million in Private Placement of Shares 95
Auspex Pharma Raises USD203.4 Million in Public Offering of Shares 96
Auspex Pharma Raises USD69.7 Million in Public Offering of Shares 98
Auspex Pharma Completes IPO For US$96.6 Million 100
Teva Pharma Prices Private Placement of 6% Notes Due 2024 for USD1.25 Billion 102
Teva Pharma Prices Private Placement of 6.75% Notes Due 2028 for USD1.25 Billion 103
Teva Pharma Prices Private Placement of 3.25% Notes Due 2022 for USD866.3 Million 104
Teva Pharma Prices Private Placement of 4.5% Notes Due 2025 for USD1,113.8 Million 105
Teva Pharma Plans to Raise USD5,000 Million in Public Offering of Debt Securities 106
Teva Pharma Raises USD304 Million in Public Offering of 0.125% Notes Due 2018 107
Teva Pharma Raises USD354.6 Million in Public Offering of 1% Notes Due 2025 109
Teva Pharma Raises USD354.6 Million in Public Offering of 0.5% Notes Due 2022 111
Teva Pharma Raises USD1.65 Billion in Additional Public Offering of 1.125% Notes Due 2024 113
Teva Pharma Raises USD1.93 Billion in Additional Public Offering of 0.375% Notes Due 2020 115
Teva Pharma Raises USD820 Million in Additional Public Offering of 1.625% Notes Due 2028 117
Teva Pharma Raises USD3 Billion in Public Offering of 2.8% Notes Due 2023 119
Teva Pharma Raises USD1.5 Billion in Public Offering of 1.4% Notes Due 2018 121
Teva Pharma Raises USD2 Billion in Public Offering of 1.7% Notes Due 2019 123
Teva Pharma Raises USD2 Billion in Public Offering of 4.1% Notes Due 2046 125
Teva Pharma Raises USD3.5 Billion in Public Offering of 3.15% Notes Due 2026 127
Teva Pharma Raises USD3 Billion in Public Offering of 2.2% Notes Due 2021 129
Teva Pharma Plans to Raise USD22 Billion in Public Offering of Bonds 131
Teva Pharma Raises USD1.4 Billion in Public Offering of 1.25% Senior Notes Due 2023 132
Teva Pharma Raises USD760 Million in Public Offering of 1.875% Senior Notes Due 2027 133
Teva Pharma Completes Public Offering Of Notes Due 2020 For US$700 Million 134
Teva Pharma Completes Public Offering Of Notes Due 2022 For US$1.3 Billion 136
Teva Pharma Completes Public Offering Of Senior Notes Due 2018 For US$495 Million 138
Teva Pharma Completes Public Offering Of Senior Notes Due 2019 For US$1.3 Billion 140
89bio Acquires NASH Assets from Teva Pharma 142
NeuroSearch Sells Rights for Pridopidine to Teva Pharma 143
Super-Pharm May Acquire Ashdod Plant from Teva Pharma Industries 144
Foundation Consumer Healthcare Acquires Women Health Products from Teva Pharma for USD675 Million 145
Teva Pharma May Sell European Oncology and Pain Assets 146
Intas Pharma and Aurobindo Pharma May Acquire Europen Divisions from Teva Pharma 147
Teva Pharma May sell Medis Unit 148
OncBioMune Pharma Acquire Norepinefrine in Mexico from Teva Pharma 149
Teva Pharma Sells Assets and Operations of Actavis Generics in UK and Ireland to Accord Healthcare 150
Arrow Generiques to Acquire Select Commercial Products in France from Teva Pharma 152
Sagent Pharma Acquires Product Portfolio from Teva Pharma and Actavis for USD40 Million 153
Mayne Pharma Acquires US Generic Products from Teva Pharma and Allergan for USD652 Million 154
Impax Labs Acquires Generic Products from Teva Pharma and Allergan for USD586 Million 156
Dr. Reddy’s Labs Acquires Portfolio of Eight ANDAs from Teva Pharma for USD350 Million 158
Cipla and Aurobindo Acquires Certain Generic Products Rights in the US from Teva Pharma 160
Perrigo Acquires Remaining 60.9% Rights of Benzaclin from Barr Labs for USD62 Million 161
Prasco to Acquire Authorized Generic of Adderall XR Capsules from Teva Pharma and Shire 162
Zydus Cadila Healthcare Announces Acquisition of Two Abbreviated New Drug Applications form Teva Pharma 163
Saniona Acquires ACR325 and ACR343 Drugs from NeuroSearch 164
Teva Pharma May Divest its Assets 165
Ferring Pharma Acquires Global Rights to Milprosa from Teva Women's Health 167
ANI Pharma Acquires Rights to Testosterone Gel 1% from Teva Pharma 168
Amneal Pharma Acquires Generic Business of Actavis Australia 169
Teva Pharma Plans to Divest Some Operations 170
Ignyta Acquires Four Oncology R&D Assets from Cephalon 171
ANI Pharma Acquires ANDA from Teva Pharma 173
Teva Pharma to Sell its Manufacturing Facility in Sellersville, Pennsylvania to G&W Labs 174
Saniona Acquires Assets from NeuroSearch 175
ANI Pharma Acquires 22 Generic Drug Products from Teva Pharma 176
Amedra Pharmaceuticals Acquires Mebendazole Tablet Product from Teva Pharmaceutical 177
Teva Pharma Plans To Sell Manufacturing Facility In Irvine, California 178
CleveXel Pharma Acquires Development Center From Teva Pharma 179
Saniona Acquires Technical Platforms from NeuroSearch 180
Procter & Gamble Receives EC Approval To Acquire OTC Business Of Teva Pharma 181
Teva Completes Acquisition Of Huntexil Development Program Rights From NeuroSearch For US$26 Million 182
Aniona Acquires Portfolio of Preclinical Assets from NeuroSearch 184
Halo Pharma Completes Acquisition Of Mirabel Manufacturing Facility From Teva Canada 185
Hi-Tech Pharmacal Acquires Rights To Cormax From Watson Labs 186
Biolab Sanus Farmaceutica Acquires Actavis Farmaceutica from Teva Pharma and Actavis Dutch 187
NeuroSearch Plans to Sell Itself 188
Allergan to Sell 10% Stake in Teva Pharma 189
Teva Pharma Sells Stake in Mesoblast 190
Jiaxing Yun Shi Tai Yu Investment to Acquire 20% Stake in Tianjin Sinobioway Biomedicine from Tianjin Zhongxin Pharma 191
Clal Biotech to Acquire 5% Stake in Gamida Cell from Teva Pharma 192
Teva Pharma Acquires Anda from Allergan for USD500 Million 193
Teva Pharma, Mylan May Acquire Teut|Pfizer 194
Teva Pharma Acquires Rimsa for USD2.3 Billion 196
Auspex Pharma Acquires Imphar 197
Teva Pharma Acquires Gecko Health Innovations 198
Teva Pharma to Acquire 51% Stake in Immuneering 199
Teva Pharma Acquires Auspex Pharma 200
Teva Pharma Completes Acquisition of Labrys Biologics 202
Teva Pharma Completes Acquisition Of NuPathe 203
Zhejiang Chiral Medicine Chemicals To Acquire Stake In Actavis (Foshan) Pharma From Actavis 205
Teva Pharma Completes Acquisition of MicroDose Therapeutx 206
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 207
BioTime Acquires 62.6% Stake in Cell Cure Neurosciences for USD3.5 Million 209
XTL Biopharma Acquires 31% Stake In Proteologics From Teva For US$2 Million 211
Teva Pharma Rumored To Acquire Amarin 212
Watson Pharma Acquires Ascent Pharmahealth From Strides Arcolab And Dennis Bastas For US$394 Million 213
Teva Pharmaceutical Industries Ltd, Key Competitors 215
Teva Pharmaceutical Industries Ltd, Key Employees 216
Teva Pharmaceutical Industries Ltd, Subsidiaries 218
Teva Pharmaceutical Industries Ltd, Joint Venture 226

List of Figures
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 12
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 13
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 14
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 15
Teva Pharmaceutical Industries Ltd, Medical Devices Deals, 2012 to YTD 2018 17

★海外企業調査レポート[Teva Pharmaceutical Industries Ltd (TEVA)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • PDC Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    PDC Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary PDC Energy Inc (PDC Energy) is an oil and gas company that offers production, development, exploration and marketing of crude oil, natural gas and natural gas liquids. The company provides horizontal …
  • AEON Credit Service (Asia) Co., Ltd.：企業の戦略・SWOT・財務情報
    AEON Credit Service (Asia) Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary AEON Credit Service (Asia) Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Sygnis AG (LIO1)：医療機器：M&Aディール及び事業提携情報
    Summary Sygnis AG (Sygnis), formerly Sygnis Pharma AG is a developer of novel products and tools in the field of molecular biology. The company undertakes development and marketing of new molecular biological technologies for DNA amplification and sequencing. Its offers products such as single cell …
  • MEDICREA Group (ALMED)：企業の財務・戦略的SWOT分析
    Summary MEDICREA Group (MEDICREA) is a medical equipment company that provides surgical solutions to neurosurgeons and orthopedic surgeons. The company designs, manufactures and distributes proprietary technologies related to patient specific spinal surgery. It offers products such as polyaxial spin …
  • Dusit Thani Public Company Limited：企業の戦略・SWOT・財務情報
    Dusit Thani Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary Dusit Thani Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Murree Brewery Co. Ltd.：企業の戦略・SWOT・財務情報
    Murree Brewery Co. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Murree Brewery Co. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Compuware Corp：企業の戦略・SWOT・財務情報
    Compuware Corp - Strategy, SWOT and Corporate Finance Report Summary Compuware Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Pioneer Energy Services Corp (PES)：企業の財務・戦略的SWOT分析
    Pioneer Energy Services Corp (PES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Enbridge Inc (ENB)：企業の財務・戦略的SWOT分析
    Enbridge Inc (ENB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Phagelux Inc-製薬・医療分野：企業M&A・提携分析
    Summary Phagelux Inc (Phagelux) is an anti-infectives company that provides antibacterial products and solutions. The company uses phage lysis enzymes and biological agents for the treatment of antibiotic resistant bacteria and related diseases in human beings and crops. Its product portfolio includ …
  • Graftobian Makeup Company：企業の戦略・SWOT・財務情報
    Graftobian Makeup Company - Strategy, SWOT and Corporate Finance Report Summary Graftobian Makeup Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • BlueScope Steel Ltd：企業のM&A・事業提携・投資動向
    BlueScope Steel Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BlueScope Steel Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Chesswood Group Ltd (CHW)：企業の財務・戦略的SWOT分析
    Chesswood Group Ltd (CHW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Kawasumi Laboratories Inc (7703)：企業の財務・戦略的SWOT分析
    Summary Kawasumi Laboratories Inc (Kawasumi) is a medical device company that manufactures and distributes disposable blood collection and transfusion sets. The company’s product portfolio includes hemodialysis, plasmapheresis, blood banking and transfusion, infusion therapy, andendovascular repair …
  • Enerchem International Inc：企業の戦略的SWOT分析
    Enerchem International Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Alliant Credit Union：企業の戦略的SWOT分析
    Alliant Credit Union - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Hindustan Aeronautics Ltd：企業の戦略・SWOT・財務情報
    Hindustan Aeronautics Ltd - Strategy, SWOT and Corporate Finance Report Summary Hindustan Aeronautics Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Sandoz Inc：企業のM&A・事業提携・投資動向
    Sandoz Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sandoz Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Secom Co Ltd (9735)：企業の財務・戦略的SWOT分析
    Secom Co Ltd (9735) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Barrick Gold Corporation：戦略・SWOT・企業財務分析
    Barrick Gold Corporation - Strategy, SWOT and Corporate Finance Report Summary Barrick Gold Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆